Boston Scientific adopts 2023 annual bonus and performance share programs

BOSTON SCIENTIFIC CORP

2023 Annual Bonus Plan ties cash incentive to adjusted EPS, global sales (constant currency), ESG scorecard, and quality assessment.
Bonus pool funding ranges from 0% to 150% of aggregate targets; CEO may adjust unit funding ±10%.
2023 rTSR PSP awards RSUs based on three-year TSR vs S&P 500 Healthcare Index (0-200% of target).
2023 Organic Net Sales PSP uses three-year organic sales growth vs plan (0-200% of target); replaces prior free cash flow program.
All awards subject to recoupment policy for misconduct or financial restatement under Dodd-Frank clawback.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.